VahatiCor’s A-Flux Reducer System Implanted in First Patient to Treat Angina

February 26, 2024—VahatiCor, Inc. announced the treatment of the first patient with the A-Flux reducer system, which is intended to treat patients with angina.

According to the company, the A-Flux reducer implant is placed in the coronary sinus. It is designed to provide more blood flow to the ischemic portion of the heart and improve patient symptoms and quality of life. A prospective multicenter clinical study of the device is scheduled to begin enrollment this year.

The first patient who received the A-Flux reducer implant was treated through the Special Access Program of Health Canada.

Jean-Michel Paradis, MD, and Can Manh Nguyen, MD, cotreated the first patient. Dr. Paradis is a specialist in coronary and structural interventional cardiology and Dr. Nguyen is an interventional cardiologist at Quebec Heart and Lung Institute in Quebec City, Canada.

“We have many interventional or surgical revascularization options for patients with advanced large coronary artery disease,” commented Dr. Paradis in VahatiCor’s press release. “However, a significant proportion still suffer from angina. The A-Flux reducer could help to fill that therapeutic void. It was an honor to perform the first-in- human implant and the patient is doing great.”

Dr. Nguyen added, “The A-Flux reducer system is a promising intervention with the potential to provide a predictable and low-risk treatment for a growing population of patients with angina symptoms that do not respond well to medicines and lifestyle changes.”